Clinical Trial Update session Sunday June 18

CLINICAL TRIAL UPDATE

08.00 - 09.15 hours, Room Y

CHRONIC MYELOID LEUKEMIA - "IMATINIB TRIALS IN CML"
Chair: Prof. Michele Baccarani (University of Heidelberg, Mannheim, Germany)

• COMPARISON OF IMATINIB WITH IMATINIB IN COMBINATION
  A. Hochhaus (University of Heidelberg, Heidelberg, Germany)
• TREATMENT OPTIMISATION AND THERAPY OF IMATINIB RESISTANT CML WITH DASATINIB AND AMN107
  M. Baccarani (University of Bologna, Bologna, Italy)
• BCR-ABL PEPTIDE VACCINATION IN TREATED CML
  R.E. Clark (Royal Liverpool University Hospital, Liverpool, United Kingdom)
• OUTCOME OF ALLOGENIC TRANSPLANTATION AFTER IMATINIB PRE-TREATMENT
  M.W.N. Deininger (Oregon Health and Science University, Portland, USA)

CLINICAL TRIAL UPDATE

10.30 - 11.45 hours, Room Y

PHASE II STUDIES IN ACUTE MYELOID LEUKEMIA: A PROGRESS UPDATE
Chair: B. Löwenberg (Erasmus Medical Center, Rotterdam, The Netherlands)

• CLOFARABINE
  A.K. Burnett (University of Wales, College of Medicine, Cardiff, United Kingdom)
• A PHASE II TRIAL OF CEP-701, AN ORAL FLT3 INHIBITOR, ADMINISTERED IN SEQUENCE WITH CHEMOTHERAPY: CLINICAL RESPONSE CORRELATES WITH FLT3 INHIBITION
  M. Levis (Johns Hopkins University, Baltimore, USA)
• TIPIFARNIB
  J.E. Karp (John Hopkins University, Baltimore, USA)
• DECITABINE
  M. Lubbert (University Freiburg Medical Center, Freiburg, Germany)
• BORTEZOMIB
  P. Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)